U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

NO-711

MORE DETAILS

  BGU9MZ2G30

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sodium- and chloride-dependent GABA transporter 1
2
Conditions:
Anti-amnesia
2
Cognitive-enhancement
2
Neuro-psychiatric disorders
2
NO-711 (aka NNC-711) is an anticonvulsant under development by Novo Nordisk. It acts as a gamma-aminobutyric acid (GABA) uptake inhibitor by inhibiting GAT-1. It has been investigated as a potential therapeutic agent for a number of cognitive disorders, as well as the potential to improve normal cognitive functions.

NNC-711

MORE DETAILS

  500M0G931K

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sodium- and chloride-dependent GABA transporter 1
2
Conditions:
Anti-amnesia
2
Cognitive-enhancement
2
Neuro-psychiatric disorders
2
NO-711 (aka NNC-711) is an anticonvulsant under development by Novo Nordisk. It acts as a gamma-aminobutyric acid (GABA) uptake inhibitor by inhibiting GAT-1. It has been investigated as a potential therapeutic agent for a number of cognitive disorders, as well as the potential to improve normal cognitive functions.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966